UT College of Pharmacy and Pharmaceutical Sciences News

Posts Tagged ‘pharmacology’

Meet Dr. Salah Ahmed

Dr. Salah Ahmed

Dr. Salah Ahmed

Dr. Salah Ahmed is an assistant professor in the Department of Pharmacology. Dr. Ahmed’s Arthritis Research lab is funded by the grants from NIH and pharmaceutical industry. His group has published research work in high-impact journals including Proceedings of the National Academy of Sciences, USA, Arthritis & Rheumatism, Journal of Pharmacology & Experimental Therapeutics, Molecular Interventions, and Frontiers in Immunology.

Dr. Ahmed has been invited to serve as a reviewer for the NIH and Arthritis Foundation grants. Currently, he also serves as a Lead Guest Editor on the Special Issue of the journal Mediators of Inflammation and as an expert reviewer for several journals. Dr. Ahmed has received awards from the American Society for Pharmacology and Experimental Therapeutics (ASPET), the American College of Rheumatology (ACR), and the International Union of Pharmacology (IUPHAR).

Rheumatoid arthritis (RA), a chronic inflammatory joint disorder, is a leading cause of work-related disabilities and a significant socio-economic health challenge due to expensive, yet incomplete, conventional therapies. Using synovial fibroblasts isolated from RA patients and animal models of human RA, we are testing the efficacy of epigallocatechin-3-gallate (EGCG), a potential anti-inflammatory molecule found in green tea, in regulating the synthesis and detrimental effects of interleukin-6 (IL-6) in RA. The success of the proposed experiments may lead to a significant advancement in the development of EGCG as a potentially safe and inexpensive treatment option for RA.

Dr. Ahmed has received a five-year R01 NIH funding to study the mechanisms through which EGCG inhibits inflammation and tissue destruction in RA. Patients suffering from RA tend to develop cardiovascular complications. His research focus in this area is to study the role of pro-inflammatory cytokines and downstream inflammatory mediators in the manifestation of cardiovascular complications in RA. Based on these findings, his lab plans to test potential novel anti-inflammatory molecules in clinical intervention studies. The success of these studies may lead to a significant advancement in the development of EGCG or structurally related molecules as potential treatment options for RA and possibly other autoimmune diseases.

Dr. Ahmed’s most rewarding contribution has been the training of undergraduates and graduates for research careers in pharmacology and experimental therapeutics. He has trained students who went on to publish research and review articles, present posters at the scientific meetings, and successfully enter PhD programs of various research universities.

Dr. Wayne Hoss’s Retirement

Dr. Wayne HossDr. Wayne Hoss, executive associate dean of the College of Pharmacy and Pharmaceutical Sciences, will retire in June 2013 after 28 years of service to the university. Dr. Hoss joined the faculty of The University of Toledo in 1985 as a professor of medicinal chemistry. He later added the responsibility of co-directing the Center for Drug Design and Development for a brief period before spending nearly a decade as the university’s associate vice president for research and development. Dr. Hoss returned to the College of Pharmacy and Pharmaceutical Sciences in 1999 as the interim dean before taking on the role of associate dean and later executive associate dean, the position he now holds.

Dr. Hoss’s leadership and vision have been a driving factor behind many of the college’s successes over the years. He is involved in every aspect of the college, from research and graduate studies to ensuring that the college’s facilities are the best in the region and that the college exceeds the standards set by its accrediting body.

In addition to his roles in academia, Dr. Hoss remains closely involved in research. He is a director at Mithridion, Inc., a biopharmaceutical company that focuses on treatments for neurological and psychiatric disorders, including Alzheimer’s disease and schizophrenia.

New Experimental Therapeutics PhD Program

The Department of Pharmacology in the College of Pharmacy and Pharmaceutical Sciences at the University of Toledo has received formal approval for implementing a Ph.D. program in Experimental Therapeutics.

Experimental Therapeutics is the integration of basic and applied sciences focused on the study and development of new treatments for human disease. Research in experimental therapeutics seeks to understand human diseases from the molecular level to the whole organism in order to develop rational approaches for new pharmacological treatments. In addition, experimental therapeutics includes the development of new therapies through systematic investigation at increasing levels of complexity, ranging from individual molecules and proteins to cellular and tissue-based assays and to the whole organism. The purpose of the program is to train students at the doctoral level who can translate discoveries in the laboratory to therapies in a clinical setting.

The program provides a bridge between the Ph.D. in Medicinal Chemistry and Doctor of Pharmacy (Pharm.D.) degrees, and matches the strengths of our educational and research environment.

By its very nature, Experimental Therapeutics is a multi-disciplinary field, drawing on a variety of scientific areas, including but not limited to pharmacology, toxicology, biochemistry, medicinal chemistry, cell and molecular biology, neuroscience, physiology, immunology, pharmaceutics, pathology, statistics and engineering. As such, our program is open to faculty from a number of disciplines outside the Department of Pharmacology, thus enhancing the potential research experience of our students. Examples include developing collaborations between Drs. Surya Nauli, Department of Pharmacology, and Bina Joe in the Department of Physiology and Pharmacology in the area of hypertension and between Drs. Youssef Sari, Department of Pharmacology, and Bryan Yamamoto in the Department of Neurosciences in the area of drug and alcohol abuse.

The program received formal approval by the Chancellor of the Ohio Board of Regents in late August, thus culminating a lengthy process of program development that involved multiple levels of review both within the university and by other institutions throughout state.  Feedback from colleagues across both UT campuses as well as input from faculty at other universities helped in the development of a doctoral program that builds upon the strengths of research and educational programs on the Health Sciences Campus.

The new program will provide unique opportunities for faculty in the Department of Pharmacology to train doctoral students in translational research that is focused on developing new treatments for neurological disorders such as Alzheimer’s disease and drug abuse, immune disorders such as diabetes and myasthenia gravis, and other human diseases including cancer, polycystic kidney disease and hypertension.


Faculty Notes: September 2011

Dr. Ahmed

Dr. Ahmed

Dr. Salah-Uddin Ahmed, assistant professor of pharmacology, researches novel therapeutic uses for commonly consumed items like chocolate and green tea. His research has shown that chocolate is effective in limiting brain damage due to stroke and that green tea is an effective remedy for arthritis. Dr. Ahmed recently shared his expertise on the progression and treatment of rheumatoid arthritis with WGTE viewers. UTCPPS students and laboratories are also featured in the video.  Watch the video

Dr. Aaron Lengel is the new advisor for the Beta Eta chapter of the Rho Chi Society, the academic honor society in pharmacy.